BIOMIND LABS INC. (3XI) - Net Assets

Latest as of September 2025: €-1.56 Million EUR ≈ $-1.82 Million USD

Based on the latest financial reports, BIOMIND LABS INC. (3XI) has net assets worth €-1.56 Million EUR (≈ $-1.82 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€57.72K ≈ $67.47K USD) and total liabilities (€1.62 Million ≈ $1.89 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check 3XI goodwill-adjusted equity ratio to evaluate the tangible quality of the company's equity base.

Key Net Assets Metrics

Metric	Value
Current Net Assets	€-1.56 Million
% of Total Assets	-2702.98%
Annual Growth Rate	N/A
5-Year Change	N/A
10-Year Change	N/A
Growth Volatility	N/A

BIOMIND LABS INC. - Net Assets Trend (2021–2024)

This chart illustrates how BIOMIND LABS INC.'s net assets have evolved over time, based on quarterly financial data. Explore cash efficiency ratio of BIOMIND LABS INC. to assess how effectively this company generates cash.

Annual Net Assets for BIOMIND LABS INC. (2021–2024)

The table below shows the annual net assets of BIOMIND LABS INC. from 2021 to 2024. For live valuation and market cap data, see market cap of BIOMIND LABS INC..

Year	Net Assets	Change
2024-12-31	€-1.30 Million ≈ $-1.52 Million	+9.21%
2023-12-31	€-1.43 Million ≈ $-1.67 Million	-478.27%
2022-12-31	€-247.66K ≈ $-289.54K	-111.29%
2021-12-31	€2.19 Million ≈ $2.56 Million	--

Equity Component Analysis

This analysis shows how different components contribute to BIOMIND LABS INC.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have decreased by 443843300.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (December 2024)

Component	Amount	Percentage
Other Components	€13.58 Million	%
Total Equity	€-1.30 Million	100.00%

BIOMIND LABS INC. Competitors by Market Cap

The table below lists competitors of BIOMIND LABS INC. ranked by their market capitalization.

Company	Market Cap
ODI PHARMA AB F:6OD	$3.31 Million
KWANGJIN WINTEC CO. Ltd KQ:090150	$3.32 Million
Axilion Smart Mobility Ltd TA:AILN	$3.32 Million
Gore Street Energy Storage Fund Plc LSE:GSF	$3.32 Million
WOODPECKER.CO ZY -10 F:8FG	$3.31 Million
N2OFF Inc NASDAQ:NITO	$3.31 Million
Coloseum Holding a.s. PR:COLOS	$3.31 Million
Vanquis Banking Group PLC LSE:VANQ	$3.31 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in BIOMIND LABS INC.'s equity between the two most recent reporting periods.

Equity Growth Insights

From 2023 to 2024, total equity changed from -1,432,120 to -1,300,192, a change of 131,928.
Net loss of 260,479 reduced equity.
Other factors increased equity by 392,407.

Equity Change Factors (2023 to 2024)

Factor	Impact	Contribution
Net Income	€-260.48K	-20.03%
Other Changes	€392.41K	+30.18%
Total Change	€-	%

Book Value vs Market Value Analysis

This analysis compares BIOMIND LABS INC.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2021-12-31	€0.03	€0.04	x
2022-12-31	€0.00	€0.04	x
2023-12-31	€-0.02	€0.04	x
2024-12-31	€-0.02	€0.04	x

Capital Efficiency Dashboard

This dashboard shows how efficiently BIOMIND LABS INC. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): 0.00%
The company may be facing challenges in efficiently utilizing shareholder equity.
DuPont Analysis Breakdown:
• Net Profit Margin: 0.00%
• Asset Turnover: 0.00x
• Equity Multiplier: 0.00x
Recent ROE (0.00%) is above the historical average (-49.39%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2021	-197.55%	0.00%	0.00x	1.15x	€-4.55 Million
2022	0.00%	0.00%	0.00x	0.00x	€-2.96 Million
2023	0.00%	0.00%	0.00x	0.00x	€-1.05 Million
2024	0.00%	0.00%	0.00x	0.00x	€-130.46K

Industry Comparison

This section compares BIOMIND LABS INC.'s net assets metrics with peer companies in the Biotechnology industry.

Industry Context

Industry: Biotechnology
Average net assets among peers: $2,083,584,994
Average return on equity (ROE) among peers: -84.09%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
BIOMIND LABS INC. (3XI)	€-1.56 Million	-197.55%	N/A	$3.31 Million
PROQR THERAPEUTICS EO-04 (0PQ)	$49.37 Million	-85.44%	1.28x	$142.34 Million
TIZIANA LIFE SCIENCES LTD (0RP)	$3.94 Million	-301.40%	1.87x	$161.62 Million
Theravance Biopharma Inc (0TB)	$-223.84 Million	0.00%	0.00x	$787.91 Million
I-MAB SPONS.ADS/1 -0001 (0VY)	$230.94 Million	-20.03%	0.13x	$197.40 Million
PreveCeutical Medical Inc (18H)	$-344.34K	0.00%	0.00x	$3.34 Million
Argen-X (1AE)	$538.39 Million	-12.38%	0.07x	$41.67 Billion
WAVE LIFE SCIENCES LTD. (1U5)	$32.50 Million	-376.16%	5.37x	$1.14 Billion
BIOCURE TECHNOLOGY INC. (1WH)	$-2.33 Million	0.00%	0.00x	$960.84K
ZAI LAB LTD0000006 (1ZLB)	$796.12 Million	-42.03%	0.30x	$1.82 Billion
BioNTech SE (22UA)	$19.41 Billion	-3.43%	0.16x	$20.05 Billion

About BIOMIND LABS INC.

F:3XI Germany Biotechnology

Market Cap

$3.31 Million

€2.83 Million EUR

Market Cap Rank

#29221 Global

#2549 in Germany

Share Price

€0.04

Change (1 day)

+0.00%

52-Week Range

€0.04 - €0.20

All Time High

€1.25